NCT05301751View on ClinicalTrials.gov

A Single Ascending Dose Cohort Study of AG-73305 in DME Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

September 28, 2023

Study Completion Date

December 26, 2023

Conditions
Diabetic Macular Edema
Interventions
BIOLOGICAL

AG-73305

drug product solution

Trial Locations (6)

33711

Retina Vitreous Associates of Florida, St. Petersburg

33880

Center of Macula and Retina Disease, Winter Haven

76087

Strategic Clinical Research Group, LLC, Willow Park

76104

Texas Retina Associates, Fort Worth

78503

Valley Retina Institute, McAllen

79606

Retina Research Institute of Texas, Abilene

Sponsors
All Listed Sponsors
collaborator

Lexitas Pharma Services, Inc.

INDUSTRY

lead

Allgenesis Biotherapeutics Inc.

INDUSTRY

NCT05301751 - A Single Ascending Dose Cohort Study of AG-73305 in DME Patients | Biotech Hunter | Biotech Hunter